Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry

Although new multiple myeloma (MM) therapies are effective in alleviating some disease‐associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health‐related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalido...

Descripción completa

Detalles Bibliográficos
Autores principales: Abonour, Rafat, Rifkin, Robert M., Gasparetto, Cristina, Toomey, Kathleen, Durie, Brian G. M., Hardin, James W., Terebelo, Howard R., Jagannath, Sundar, Narang, Mohit, Ailawadhi, Sikander, Omel, James L., Lee, Hans C., Srinivasan, Shankar, Kitali, Amani, Agarwal, Amit, Wagner, Lynne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048460/
https://www.ncbi.nlm.nih.gov/pubmed/33118614
http://dx.doi.org/10.1111/bjh.17131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048460/
https://www.ncbi.nlm.nih.gov/pubmed/33118614
http://dx.doi.org/10.1111/bjh.17131

Ejemplares similares